Biocytogen’s antibody business development and licensing (BDL) team is excited to host 1-on-1 meetings at Bio International Convention 2024, taking place from June 3-6, 2024 in San Diego, CA!
—————————————————————————————————————————————————————————————————————————————
Our Fully Human Library. Your Pipeline.
Leveraging our proprietary RenMice® discovery platforms, Biocytogen has generated a vast antibody library consisting of 400k+ fully human antibody sequences against hundreds of therapeutic targets. This antibody sequence library, as well as individual antibody-based assets, are available for partnership:
- 40+ PCC-stage antibody assets: B7-H3, Siglec-15, TNFR2, MUC16, NKG2D, ROR1, TIGIT, IL-2RA, AMHR2, CD73, CD40 (antagonist), and more；
- 80+ TAA antibodies for plug-and-play development: TSPAN8, SLC34A2, MUC1, 5T4 (TPBG), PTK7, FOLR1, CEACAM6, PSMA, CDH3, DLL3, SEZ6, HER3, HLA-G, LIV-1, and more；
- 10+ fully human bsAbs: 4-1BB x CD40 bsAb, TIGIT x IL-21 fusion protein for oncology, OX40 x OX40 (biparatopic) bsAb for autoimmunity, and more;
- 20+ bsADCs: PTK7 x TROP2 bsADC, HER3 x MET bsADC, PTK7 x EGFR bsADC, PTK7 x B7-H3 bsADC, and more;
- 10+ TCR-mimic antibodies: WT1, KRAS (G12V, G12D), NY-ESO-1, AFP, GP100, LMP2, Survivin 2B and other intracellular targets in the context of HLA-A02, HLA-A03, HLA-A11, or HLA-A24;
- 90+ nanobodies and our “Nano 100 Project”: TFR1 (blood-brain-barrier crossing), 4-1BB, OX40, BCMA, and more;
- 70+ fully human GPCR mAb/bsAb programs: CCR8, GPRC5D, GIPR, LGR5, CCR2, and more;
- 5 clinical-stage assets: PD-1×CD40 bsAb (YH008), CD40 agonistic mAb (YH003), CTLA-4 mAb (YH001), OX40 mAb (YH002), 4-1BB mAb (YH004).
In addition, Biocytogen offers licensing and flexible partnering models for its RenMice® fully human antibody/TCR discovery platforms:
Biocytogen’s antibody assets and RenMice platforms have been widely recognized by global companies. As of December 31, 2023, we have successfully established 103 therapeutic antibody agreements and 47 target-nominated RenMice® licensing projects worldwide. The asset partnerships include our mAbs, bsAbs, bsADCs, nanobodies, TCR-mimic antibodies and anti-GPCR antibodies.
—————————————————————————————————————————————————————————————————————————————
Interested in exploring partnership opportunities with us to benefit your drug discovery and development? Contact us today!
